REGENERA Research Group

International Journal of Inflammation, Cancer and Integrative Therapy

High Risk of Acute Exacerbation of Interstitial Lung Disease In Relapsed Small Cell Lung Cancer Treated With Amrubicin

Abstract

Author(s): Niwa H

Lung cancer is the leading cause of death from cancer worldwide. Small cell lung cancer (SCLC) accounts for 15% to 20% of lung cancer. SCLC is characterized by a high rate of invasion and rapid cell proliferation. The SCLC also shows a high sensitivity to chemotherapy and radiotherapy; however, the duration of the response is relatively short. The standard chemotherapy regimen for SCLC patients is a combination of platinum and etoposide agents or platinum agents plus irinotecan, which is the most frequently used combination and gives a median survival period of approximately 9 to 12 months in clinical trials.